Aromasin and Hip joint replacement - a phase IV clinical study of FDA data

Summary:

Hip joint replacement is reported as a side effect among people who take Aromasin (exemestane), especially for people who are female, 30-39 old, also take Aredia, and have Bone density decreased.

The phase IV clinical study analyzes which people have Hip joint replacement when taking Aromasin. It is created by eHealthMe based on reports of 12,620 people who have side effects when taking Aromasin from the FDA, and is updated regularly.

What is Aromasin?

Aromasin has active ingredients of exemestane. It is often used in breast cancer. eHealthMe is studying from 12,863 Aromasin users. Check the latest studies of Aromasin.

What is Hip joint replacement?

Hip joint replacement is found to be associated with 891 drugs and 1,037 conditions by eHealthMe. Check the latest studies of Hip joint replacement.



On Nov, 05, 2025

12,620 people reported to have side effects when taking Aromasin.
Among them, 12 people (0.1%) have Hip joint replacement.

Could Aromasin cause Hip joint replacement?

Among these 12 people:

What is the gender of people who have Hip joint replacement when taking Aromasin? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Hip joint replacement when taking Aromasin? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 60 %
  • 40-49: 0.0 %
  • 50-59: 40 %
  • 60+: 0.0 %

What are other drugs people take besides Aromasin? *

  1. Arimidex: 11 people, 91.67%
  2. Percocet: 11 people, 91.67%
  3. Zometa: 11 people, 91.67%
  4. Aredia: 11 people, 91.67%
  5. Enoxaparin Sodium: 6 people, 50.00%
  6. Zoladex: 6 people, 50.00%
  7. Xeloda: 6 people, 50.00%
  8. Magnesium: 6 people, 50.00%
  9. Retin-A: 5 people, 41.67%
  10. Ranitidine: 5 people, 41.67%

What are other side effects people have besides Hip joint replacement? *

  1. Weakness: 11 people, 91.67%
  2. Joint Pain: 10 people, 83.33%
  3. Rashes (redness): 10 people, 83.33%
  4. Rib Fracture: 8 people, 66.67%
  5. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 8 people, 66.67%
  6. Oedema Peripheral (superficial swelling): 8 people, 66.67%
  7. Osteonecrosis Of Jaw (death of bone of jaw): 8 people, 66.67%
  8. Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 7 people, 58.33%
  9. Metastases To Bone (cancer spreads to bone): 7 people, 58.33%
  10. Dyspnea (difficult or laboured breathing): 6 people, 50.00%

What are the existing conditions these people have? *

  1. Osteoporosis (bones weak and more likely to break): 5 people, 41.67%
  2. Bone Density Decreased: 5 people, 41.67%
  3. Immunodeficiency Common Variable: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Aromasin and have Hip joint replacement?

- Check whether Hip joint replacement is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aromasin:

Hip joint replacement treatments and more:

How severe was Hip joint replacement and when was it recovered:

Expand to all the drugs that have ingredients of exemestane:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Aromasin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hip joint replacement:

Browse all the conditions that are associated with Hip joint replacement:

Drugs similar to Aromasin and Hip joint replacement :


How the study uses the data?

The study uses data from the FDA. It is based on exemestane (the active ingredients of Aromasin) and Aromasin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: